Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation

被引：0

作者：

Ma, W. ^{[1
]}

Gong, J. ^{[1
]}

Shan, J. ^{[2
]}

Lewis, D. ^{[2
]}

Xiao, W. ^{[3
]}

Hung, J. ^{[4
]}

Moore, E. H. ^{[5
]}

Zhang, Y. ^{[6
]}

Mans, N. Z. ^{[7
]}

Welborn, J. ^{[5
]}

Lam, K. S. ^{[3
]}

Li, T. ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Sacramento, CA 95817 USA

[2] Albert Einstein Coll Med, Dept Genet, New York, NY USA

[3] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA

[4] Sierra Nevada Med Grp, Grass Valley, CA USA

[5] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA

[6] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA

[7] Univ Calif Davis, Hereditary Canc Program, Ctr Comprehens Canc, Sacramento, CA 95817 USA

来源：

关键词：

osimertinib; lung cancer; Germline EGFR T790M;

D O I：

10.1016/j.jtho.2017.09.590

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 15.08

引用

页码：S1863 / S1864

页数：2